These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 7671247)

  • 21. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
    Matsumoto Y; Takano H; Fojo T
    Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
    Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.
    Cole SP; Chanda ER; Dicke FP; Gerlach JH; Mirski SE
    Cancer Res; 1991 Jul; 51(13):3345-52. PubMed ID: 1675932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
    Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
    Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
    J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
    Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB
    Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
    Damle B; Desai P
    Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S; Austin CA; Fisher LM
    Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression.
    Versantvoort CH; Broxterman HJ; Pinedo HM; de Vries EG; Feller N; Kuiper CM; Lankelma J
    Cancer Res; 1992 Jan; 52(1):17-23. PubMed ID: 1309222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
    Nakagawa M; Schneider E; Dixon KH; Horton J; Kelley K; Morrow C; Cowan KH
    Cancer Res; 1992 Nov; 52(22):6175-81. PubMed ID: 1358431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
    Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
    Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
    Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
    Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.
    Yu Q; Mirski SE; Sparks KE; Cole SP
    Biochemistry; 1997 May; 36(19):5868-77. PubMed ID: 9153428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.